Hilary Tindle, MD, MPH, associate professor of medicine at Vanderbilt University, discusses key findings and patient attitudes toward precision approaches to quitting smoking.
Patients are generally enthusiastic about precision approaches to quitting smoking in pilot studies, and randomized controlled trials (RCTs) are ongoing, said Hilary Tindle, MD, MPH, associate professor of medicine at Vanderbilt University.
Transcript
What were some of your findings from the pilot precision RCTs you participated in, and what were patient attitudes towards them?
We have conducted a couple of pilots and we're conducting a larger clinical trial now that is not finished, it's still ongoing. But in our pilot work, one was in the hospital clinic setting and another was in the community setting through the Southern Community Cohort Study, which is a longitudinal cohort of 12 states in the South that overlaps with Tobacco Nation.
We uniformly found that people are enthusiastic about precision approaches to quitting smoking, and that's across all groups. There were some groups, of course, who were a little less enthusiastic, but that's what you're going to find with any new therapy. And all that it means is that people need to see good evidence, they need to know that what they're accepting is high-value care. But in general, most people, if they're asked, would you take a blood test if your doctor could order it, and it could help choose the best medicine for you to quit smoking? Most people endorse that with a yes.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Camlipixant May Benefit Patients With High-Burden RCC
June 25th 2025A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.
Read More